August 26, 2015
Daiichi Sankyo said on August 24 that its antibacterial agents Cravit Tablets 250 mg/500 mg and Cravit Granules 10% (levofloxacin) have been approved for an additional indication of pulmonary and other tuberculosis disorders. With the additional indication, Cravit will now...read more